Download Glioblastoma Resistance To Chemotherapy Molecular Mechanisms And Innovative Reversal Strategies Book PDF

Download full Glioblastoma Resistance To Chemotherapy Molecular Mechanisms And Innovative Reversal Strategies books PDF, EPUB, Tuebl, Textbook, Mobi or read online Glioblastoma Resistance To Chemotherapy Molecular Mechanisms And Innovative Reversal Strategies anytime and anywhere on any device. Get free access to the library by create an account, fast download and ads free. We cannot guarantee that every book is in the library.

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
  • Author : Ramasamy Paulmurugan,Tarik F. Massoud
  • Publisher :Unknown
  • Release Date :2021-06-18
  • Total pages :350
  • ISBN : 9780128215685
GET BOOK HERE

Summary : Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

New Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas
  • Author : Ali Syed Arbab
  • Publisher :Unknown
  • Release Date :2021-03-18
  • Total pages :202
  • ISBN : 9780128232767
GET BOOK HERE

Summary : New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma

Alternative Mechanisms of Multidrug Resistance in Cancer

Alternative Mechanisms of Multidrug Resistance in Cancer
  • Author : John A. Kellen
  • Publisher :Unknown
  • Release Date :2012-12-06
  • Total pages :281
  • ISBN : 9781461598527
GET BOOK HERE

Summary : Nullius in verba. . . Truth will be tested not by words. Horace (Epistles) Few read introductions except for book reviewers, who want to take a shortcut and avoid reading the book itself. However, tradition requires that the preface make public why the book was written at all (this is not supposed to include powerful reasons such as augmenting the ego of the editor and authors). Frequently, the inflationary tendency to publish in verbose length is in conflict with market forces and interest. No doubt, multidrug resistance is a "fashionable" topic, but there are many fashions displayed on the cat-walk of scientific literature. One can rationalize that the forces driving our concern with multi drug resistance reflect the frustration of pharmaceutical companies and oncologists alike: as soon as a new anticancer drug enters clinical trials, cancer cells start eluding extinction with their elaborate and successful mechanisms. Many grants have been awarded and spent, only to confirm the futility of our efforts to defeat this cellular Darwinism. Our medical and scientific training makes it hard, if not impossible, to accept that the survival of a malignant cell, alone or as part of a tissue, is part of the continuance of life. Since exposure to noxious and lethal substances is unavoidable, cells have been forced to develop a multitude of mechanisms to prevent entry or accelerate exit of such materials from intracellular space.

Cancer Drug Resistance

Cancer Drug Resistance
  • Author : Beverly A. Teicher
  • Publisher :Unknown
  • Release Date :2010-12-09
  • Total pages :617
  • ISBN : 1617376221
GET BOOK HERE

Summary : Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

Cancer Drug Resistance

Cancer Drug Resistance
  • Author : Jose Rueff,António Sebastião Rodrigues
  • Publisher :Unknown
  • Release Date :2016-02-25
  • Total pages :314
  • ISBN : 1493933450
GET BOOK HERE

Summary : This volume discusses the latest advancements and technologies used in cancer drug resistance research. Cancer Drug Resistance: Overviews and Methods contains chapters that cover topics such as: studying the mechanics of resistance to DNA damaging therapeutic drugs; studies to delineate the role of efflux transporters; expression of drug transporters; resistance to targeted therapies in breast cancer; the role of microRNAs in current pancreatic cancer treatment; and cancer exosomes as mediators of drug resistance or clinical and molecular methods in drug development and the use of bioinformatics in the management of cancer drug resistance data. Written in the highly successful Methods in Molecular Biology series format, chapters include overviews of the main issues in cancer drug resistance and the respective mechanisms, as well as introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Cancer Drug Resistance: Overviews and Methods, is a valuable resource to researchers, oncobiologists and clinical oncologists or anyone else who is interested in the study of cancer and its drug resistances.

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
  • Author : Benjamin Bonavida
  • Publisher :Unknown
  • Release Date :2013-07-04
  • Total pages :260
  • ISBN : 9781461470700
GET BOOK HERE

Summary : ​​​​​This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.

Tumor Progression and Therapeutic Resistance

Tumor Progression and Therapeutic Resistance
  • Author : Wafik S. El-Deiry
  • Publisher :Unknown
  • Release Date :2005
  • Total pages :198
  • ISBN : UVA:X030000978
GET BOOK HERE

Summary : This volume presents the entire breadth of translational cancer research and brings together members of academia and industry in the expectation of accelerating interactions and progress in the field. A variety of key topics are presented, beginning with discovery of molecular targets and pathways (oncogene, cell survival, tumor suppression, cell death), host-neoplasm interactions (cell adhesion, matrix proteases), early detection, monitoring progression, understanding tumor progression and metastasis, immune surveillance, in vivo molecular imaging, animal models, drug discovery including chemistry, high-throughput assays, mechanism determination, target validation, therapeutic window and some progress in clinical trials for more advanced agents and targets.

Glioblastoma

Glioblastoma
  • Author : Michael Iv,Tarik F. Massoud
  • Publisher :Unknown
  • Release Date :2019-01-10
  • Total pages :594
  • ISBN : 1536145882
GET BOOK HERE

Summary : Neuroimaging plays a central role in the initial diagnosis and subsequent monitoring of multimodal therapies offered to patients with glioblastoma the most malignant type of brain cancer. The authors present a comprehensive description of current state-of-the-art clinical neuroimaging for glioblastoma. They cover the basic concepts and most recent applications of clinical structural neuroimaging, as well as the latest innovations and up-and-coming techniques for functional imaging of glioblastoma patients.Few comprehensive books are available in this challenging field of clinical medicine. The co-editors are experienced academic neuroradiologists with an active interest in clinical imaging and research of glioblastoma, all within a vibrant clinical environment at Stanford University where the latest innovations in glioblastoma imaging and treatment are being developed. In compiling this book, the co-editors have called upon many of the worlds best clinical and basic neuroscientists specializing in the management of patients with this malignancy, for their expert input on the latest imaging developments and applicable research into glioblastoma.This book is intended for neuroradiologists, neuro-oncologists, neurosurgeons, radiation therapists, and other physicians and scientists engaged in the study and clinical management of patients with glioblastoma. It should also serve as a unique educational and research resource for students and more experienced practitioners alike within this rapidly evolving field.

Basilar Artery

Basilar Artery
  • Author : Tarik F. Massoud,Ramez Kirollos,Lotfi Hacein-bey
  • Publisher :Unknown
  • Release Date :2019
  • Total pages :616
  • ISBN : 1536153044
GET BOOK HERE

Summary : Perhaps no artery in the human body bears as much importance to bodily functions and life as the basilar artery, by virtue of the anatomical territories it serves. This is due to the critical nature of the physiological functions supported by the brainstem, the nearby cerebellum and cerebrum, and the severity of most pathological conditions known to affect this artery, and the risk involved in treating those conditions. This book is a comprehensive resource of knowledge on the anatomical, radiological, developmental, clinical, and technical aspects relevant to the diagnosis and treatment of basilar artery diseases.Until now, no single book has been available as a wide-ranging resource of clinically relevant information on the basilar artery, its pathology, and various treatment options. The co-editors are experienced academic clinicians with active interests in clinical neurovascular imaging and cerebrovascular surgery, who have worked within vibrant hospital and academic settings at the forefront of the best clinical practices related to diseases involving the basilar artery.The co-editors clinical experience has been acquired in centers of excellence across the USA, Europe, and the Far East. In compiling this book, the co-editors have also called upon many of the worlds best basic and clinical neuroscientists, specializing in knowledge of clinical conditions affecting the basilar artery, for their expert input on the latest clinical management of patients with diseases involving this artery.This book is intended for neuroradiologists, neurosurgeons, neurologists, neurointensivists, and other physicians and scientists engaged in the study and clinical management of patients with disease of the basilar artery and its vascular territories of the brain. It should also serve as a unique educational and research resource for students and more experienced practitioners alike within this important area of clinical medicine.

Cancer Treatment

Cancer Treatment
  • Author : Letícia Rangel
  • Publisher :Unknown
  • Release Date :2013-05-09
  • Total pages :630
  • ISBN : 9789535110989
GET BOOK HERE

Summary : Cancer Treatment: Conventional and Innovative Approaches is an attempt to integrate into a book volume the various aspects of cancer treatment, compiling comprehensive reviews written by an international team of experts in the field. The volume is presented in six sections: i) Section 1: Cancer treatment: Conventional and innovative pharmacological approaches; ii) Section 2: Combinatorial strategies to fight cancer: Surgery, radiotherapy, backytherapy, chemotherapy, and hyperthermia; iii) Section 3: The immunotherapy of cancer; iv) Section 4: Multidisciplinarity in cancer therapy: nutrition and beyond; v) Section 5: Supportive care for cancer patients; vi) Section 6: Perspectives in cancer biology and modeling. Ultimately, we hope this book can enlighten important issues involved in the management of cancer, summarizing the state-of-the-art knowledge regarding the disease control and treatment; thus, providing means to improve the overall care of patients that daily battle against this potentially lethal condition.

Immunotherapy of Cancer

Immunotherapy of Cancer
  • Author : Yoshiyuki Yamaguchi
  • Publisher :Unknown
  • Release Date :2016-02-22
  • Total pages :358
  • ISBN : 9784431550310
GET BOOK HERE

Summary : This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.

PIPAC

PIPAC
  • Author : Marc A. Reymond,Wiebke Solass
  • Publisher :Unknown
  • Release Date :2014-10-14
  • Total pages :252
  • ISBN : 9783110366617
GET BOOK HERE

Summary : Peritoneal dissemination is a common route of cancer metastasis. The benefit of administering chemotherapy directly into the peritoneal cavity is supported by preclinical and pharmacokinetic data. In comparison to intravenous (IV) treatment, intraperitoneal (IP) administration results in a several-fold increase in drug concentration within the abdominal cavity. There is now growing evidence from clinical studies showing a survival advantage for IP chemotherapy in various tumor typies, including ovarian, gastric and colorectal cancer. However, while the use of IP chemotherapy is slowly gaining acceptance, it is not universal, largely due to the greater toxicity associated with this approach. Moreover, efficacy of IP chemotherapy is limited by poor distribution within the abdominal cavity and by poor tissue penetration. A new way of IP chemotherapy is the application of cytotoxics in form of a pressurized aerosol into the abdominal of thoracic cavity. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is applied through laparoscopic access using two balloon trocars in an operating room equipped with laminar air-flow. In a first step,a normothermic capnoperitoneum is established with a pressure of 12 mmHg. A cytotoxic solution (about 10% of a normal systemic dose) is nebulized with a micropump into the abdominal cavity, and maintained for 30 min. The aerosol is then removed through a closed suction system. Applying an aerosol in the peritoneal cavity allows a homogeneous distribution of the chemotherapeutic agent within the abdomen. Furthermore, an artificial pressure gradient is generated that overcomes tumoral interstitial fluid pressure, an obstacle in cancer therapy. This results in a higher local drug concentration compared to conventional IP or IV chemotherapy. At the same time the plasma concentration of the chemotherapeutic agent remains low. In first clinical studies with limited number of patients in ovarian, gastric and colorectal cancer, as well as peritoneal mesothelioma, PIPAC has obtained encouraging tumor response rates and survival, with a low-side effects profile. Larger clinical trials are currently ongoing to examine if these data can be reproduced and extrapolated to other situations.

Molecular Advances in Diagnosis and Treatment of CNS Tumors

Molecular Advances in Diagnosis and Treatment of CNS Tumors
  • Author : Liam Chen,Ming-Tseh Lin,Zhaohui Zhang
  • Publisher :Unknown
  • Release Date :2020-12-09
  • Total pages :229
  • ISBN : 9782889661640
GET BOOK HERE

Summary :

Management of Adult Glioma in Nursing Practice

Management of Adult Glioma in Nursing Practice
  • Author : Ingela Oberg
  • Publisher :Unknown
  • Release Date :2019-01-04
  • Total pages :314
  • ISBN : 9783319767475
GET BOOK HERE

Summary : This contributed book focuses on the nursing care and considerations for the most common type of malignant brain tumours – gliomas, out of the 150 different types of brain tumours . The reader will gain specialist knowledge in understanding the disease trajectory of malignant gliomas and gain a deeper understanding of the presenting symptoms and varying treatment options of this highly malignant tumour. High grade malignant gliomas impact significantly on prognosis, with an average life expectancy of 18-24 months from diagnosis, given maximum treatment options including surgery, chemotherapy and radiotherapy. This book takes you through all current treatment options with their associated risks and intended benefits. Brain tumours affect not just the patient, but their family and carers too and this important aspect of holistic nursing care is not to be overlooked. This book encompasses first hand experiences of both a brain tumour patient living with a glioma and aspects from a carer. The structure of this book follows a typical patient pathway from presenting signs / symptoms through to MDT (multidisciplinary team) discussions to surgical techniques and radiological investigations, right through to chemotherapy, radiotherapy and palliative care including end of life care. It provides a distinct overview of the holistic needs spectrum encompassing the entire patient journey and equips the reader with learning objectives set at every chapter. Although this book is primarily aimed at Nurses working at ward level within neuro-oncology, this book is also intended to benefit professionals new to the field of specialist nursing – in particular those working with adult brain tumours and neuro-oncology.

Innovation in Pharmacy: Advances and Perspectives. September 2018

Innovation in Pharmacy: Advances and Perspectives. September 2018
  • Author : Organizer Committee IPAP18 – Salamanca
  • Publisher :Unknown
  • Release Date :2018-09-21
  • Total pages :358
  • ISBN : 9788490129760
GET BOOK HERE

Summary : This book contains the summaries of the "Innovation in Pharmacy: Advances and Perspectives" that took place in Salamanca (Spain) in September 2018. The early science of chemistry and microbiology were the source of most drugs until the revolution of genetic engineering in the mid 1970s. Then biotechnology made available novel protein agents such as interferons, blood factors and monoclonal antibodies that have changed the modern pharmacy. Over the past year, a new pharmacy of oligonucleotides has emerged from the science of gene expression such as RNA splicing and RNA interference. The ability to design therapeutic agents from genomic sequences will transform treatment for many diseases. The science that created this advance and its future promise will be discussed. Phillip Allen Sharp is an American geneticist and molecular biologist who co-discovered RNA splicing. He shared the 1993 Nobel Prize in Physiology or Medicine with Richard J. Roberts for “the discovery that genes in eukaryotes are not contiguous strings but contain introns, and that the splicing of messenger RNA to delete those introns can occur in different ways, yielding different proteins from the same DNA sequence. He works in Institute Professor Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), Cambridge, MA, US. Este libro recoge los resúmenes de la «Innovation in Pharmacy: Advances and Perspectives» que tuvo lugar en Salamanca (España) en septiembre de 2018. La ciencia primitiva de la química y la microbiología fue la fuente de la mayoría de las drogas hasta la revolución de la ingeniería genética a mediados de la década de 1970. Luego, la biotecnología puso a disposición agentes proteínicos novedosos como interferones, factores sanguíneos y anticuerpos monoclonales que han cambiado la farmacia moderna. Durante el año pasado, surgió una nueva farmacia de oligonucleótidos a partir de la ciencia de la expresión génica, como el empalme de ARN y la interferencia de ARN. La capacidad de diseñar agentes terapéuticos a partir de secuencias genómicas transformará el tratamiento de muchas enfermedades. La ciencia que creó este avance y su promesa futura será discutida. Phillip Allen Sharp es un genetista y biólogo molecular estadounidense que co-descubrió el empalme de ARN. Compartió el Premio Nobel de 1993 en Fisiología o Medicina con Richard J. Roberts por "el descubrimiento de que los genes en eucariotas no son cadenas contiguas, sino que contienen intrones, y que el empalme del ARN mensajero para eliminar esos intrones puede ocurrir de diferentes maneras, produciendo diferentes proteínas de la misma secuencia de ADN. Trabaja en el Instituto Profesor Koch Institute for Integrative Cancer Research, Instituto Tecnológico de Massachusetts (MIT), Cambridge, MA, EE. UU.

Tumor Organoids

Tumor Organoids
  • Author : Shay Soker,Aleksander Skardal
  • Publisher :Unknown
  • Release Date :2017-10-20
  • Total pages :213
  • ISBN : 9783319605111
GET BOOK HERE

Summary : Cancer cell biology research in general, and anti-cancer drug development specifically, still relies on standard cell culture techniques that place the cells in an unnatural environment. As a consequence, growing tumor cells in plastic dishes places a selective pressure that substantially alters their original molecular and phenotypic properties.The emerging field of regenerative medicine has developed bioengineered tissue platforms that can better mimic the structure and cellular heterogeneity of in vivo tissue, and are suitable for tumor bioengineering research. Microengineering technologies have resulted in advanced methods for creating and culturing 3-D human tissue. By encapsulating the respective cell type or combining several cell types to form tissues, these model organs can be viable for longer periods of time and are cultured to develop functional properties similar to native tissues. This approach recapitulates the dynamic role of cell–cell, cell–ECM, and mechanical interactions inside the tumor. Further incorporation of cells representative of the tumor stroma, such as endothelial cells (EC) and tumor fibroblasts, can mimic the in vivo tumor microenvironment. Collectively, bioengineered tumors create an important resource for the in vitro study of tumor growth in 3D including tumor biomechanics and the effects of anti-cancer drugs on 3D tumor tissue. These technologies have the potential to overcome current limitations to genetic and histological tumor classification and development of personalized therapies.

Role of Nutraceuticals in Cancer Chemosensitization

Role of Nutraceuticals in Cancer Chemosensitization
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2017-10-18
  • Total pages :398
  • ISBN : 9780128123744
GET BOOK HERE

Summary : Role of Nutraceuticals in Chemoresistance to Cancer, Volume Two, focuses on nutraceuticals, the compounds derived from natural sources, which are usually multi-targeted as a means to overcome chemoresistance. This book discusses the role of several compounds related to nutraceuticals and chemoresistance, such as curcumin, resveratrol, indole 3-carbinol, tocotrienols, ursolic acid, fisetin, celastrol, gambogic, butein, catechins and silymarin. It is a valuable resource for cancer researchers, oncologists and members of several areas of the biomedical field who are interested in understanding how to use nutraceuticals as a sensitizing agent for chemotherapy. Brings updated information on natural compounds used as specific inhibitors of cell signaling pathways as reviewed by experts in the field Presents experts analysis and summary of reported and novel findings and potential translational application in cancer patients Describes molecular mechanisms with new and helpful approaches for the readers to use in their own investigations

Tumor Microenvironment

Tumor Microenvironment
  • Author : Alexander Birbrair
  • Publisher :Unknown
  • Release Date :2020-06-25
  • Total pages :208
  • ISBN : 9783030445188
GET BOOK HERE

Summary : Revealing essential roles of the tumor microenvironment in cancer progression, this book provides a comprehensive overview of the latest research in the field. A variety of topics are covered, including metabolism in the tumor microenvironment, stellate cells and endothelial progenitors in the tumor microenvironment, as well as the effects of HIV, viral hepatitis, and inflammation in the tumor microenvironment, and more. Taken alongside its companion volumes, Tumor Microenvironment: State of the Science updates us on what we know about various aspects of the tumor microenvironment, as well as future directions. This book is essential reading for advanced cell biology and cancer biology students as well as researchers seeking an update on research in the tumor microenvironment.

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2018-11-21
  • Total pages :292
  • ISBN : 9780128127384
GET BOOK HERE

Summary : Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment

Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy

Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy
  • Author : Pawel Kalinski
  • Publisher :Unknown
  • Release Date :2017-12-22
  • Total pages :264
  • ISBN : 9783319675770
GET BOOK HERE

Summary : The tumor microenvironment has become a very important and hot topic in cancer research within the past few years. The tumor microenvironment is defined as the normal cells, molecules, and blood vessels that surround and feed a tumor cell. As many scientists have realized, studying the tumor microenvironment has become critical to moving the field forward, since there are many players in a tumor’s localized and surrounding area, which can significantly change cancer cell behavior. There is a dual relationship wherein the tumor can change its microenvironment and the microenvironment can affect how a tumor grows and spreads. Tumor Microenvironment in Cancer Progression and Cancer Therapy aims to shed light on the mechanisms, factors, and mediators that are involved in the cancer cell environment. Recent studies have demonstrated that in addition to promoting tumor progression and protecting tumor cells from the spontaneous immune-mediated rejection and different forms of cancer therapeutics, tumor microenvironment can also be a target and mediator of both standard and newly-emerging forms of cancer therapeutics. Thus, the dual role of the tumor microenvironment is the integral focus of the volume. The volume highlights the bi-directional interactions between tumor cells and non-malignant tumor component during tumor progression and treatment. It also focuses on the three groups of the reactive tumor component: stromal cells, blood vessels and the infiltrating immune cells. These three groups are discussed under the lens of their role in promoting tumor growth, shielding the tumor from rejection and from standard forms of cancer therapies. They are emerging as targets and mediators of standard and new forms of potential therapy.

Drug Resistance in Cancer Cells

Drug Resistance in Cancer Cells
  • Author : Kapil Mehta,Zahid H. Siddik
  • Publisher :Unknown
  • Release Date :2009-06-12
  • Total pages :363
  • ISBN : 0387894454
GET BOOK HERE

Summary : It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.